Drug class
Racetam nootropic; positive allosteric modulator of AMPA-type glutamate receptors
Mechanism of action
Has been reported to modulate AMPA-type glutamate receptor activity and influence cholinergic, dopaminergic and serotonergic neurotransmission. Its mechanisms in humans and clinical relevance remain incompletely established.
General use cases
- Investigational or non-approved nootropic use in some markets; aniracetam does not have a broadly recognised major-market marketing authorisation for a defined therapeutic indication.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
